3 Brexit ‘buys’: AstraZeneca plc, Compass Group plc and Severn Trent plc

These three stocks offer stunning long-term growth prospects in a post-Brexit world: AstraZeneca plc (LON: AZN), Compass Group plc (LON: CPG) and Severn Trent plc (LON: SVT).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One of the appealing aspects of buying utility stocks such as Severn Trent (LSE: SVT) is their performance during crises. In such periods, investors normally switch from a risk-on attitude to a risk-off one and seek out safer places to invest their capital. Utilities, with their robust earnings outlooks and stable business models, have huge appeal. Therefore, it’s of little surprise that Severn Trent’s shares have outperformed the FTSE 100 since the EU referendum.

Looking ahead, further outperformance could be on the cards. That’s because the outlook for the UK economy is highly uncertain and the trend described above may continue over the medium-to-long term. Furthermore, Severn Trent could also be viewed as a more obvious bid target in the coming months as the value of sterling plummets and it becomes cheaper and therefore more attractive for foreign bidders to acquire the water services company.

As well as a defensive profile and bid potential, Severn Trent also has a beta of just 0.7. This indicates that it offers a less volatile shareholder experience, thereby increasing its appeal in a post-Brexit world further still.

Navigating through tough times

Also offering a highly defensive profile is food services business Compass Group (LSE: CPG). It’s a highly efficient, well-run company which is able to demonstrate a long track record of having delivered rapidly rising earnings growth. Due to the uncertainty present in markets at the moment, this relative certainty could be worth an even greater premium than usual and Compass shares may significantly outperform the wider index.

One of the main drivers of Compass’ share price in recent years has been its dividend growth. In fact, it has risen at an annualised rate of 11% during the last five years, which is clearly well ahead of inflation. Next year, Compass is expected to grow dividends by around 10% and yet shareholder payouts are still set to equate to just 55% of profit. This indicates that further rapid dividend growth is ahead to boost its current yield of 2.3%.

Post-Brexit shot in the arm?

Living in a post-Brexit world could also be made easier by investing in AstraZeneca (LSE: AZN). That’s because the key driver of its share price in the coming years is unlikely to be the political or economic challenges faced by the UK, but rather the company’s ability to transition from having a strong pipeline to having multiple blockbuster drugs.

Although there’s no guarantee that this will happen, AstraZeneca seems to be doing all of the right things to boost its top and bottom line performance. Its acquisition programme is likely to remain ambitious, while it remains a relatively efficient business that’s investing heavily in its own research capabilities.

Due to its strong cash flow, AstraZeneca has been able to keep dividends at a generous level in recent years so that it yields 4.4% right now, even though its profitability has fallen. This income stability, plus the scope for rapidly rising dividends and a low correlation with the macroeconomic outlook, mean that AstraZeneca could be an excellent ally in an uncertain post-Brexit period.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and Severn Trent. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »